THERAPEUTIC VACCINE FOR PROSTATE CANCER

Project: Research project

Project Details

Description

Cancer of the prostate is a serious health problem both in the US and
worldwide. In the US alone approximately 165,000 new cases of prostate
cancer are diagnosed each year (Cancer Statistics 12993, CA Cancer J.
Clin. 43:7-26, 1993), new types of treatments such as immunotherapy should
be considered. The purpose of the present study is to explore the
possibility of inducing cytotoxic T lymphocyte (CTL) responses to
prostate-related antigens as a means of developing antigen-specific
immunotherapies for prostate cancer. Potential CTL antigenic epitopes
have been identified from the sequences of PSA and PAP. The
identification of these potential CTL epitopes was achieved by selecting
sequences from PSA and PAP that contain anchor binding motifs for MHC
class I molecules. Several of these peptides bind with high affinity to
purified MHC molecules. The ultimate goal of the Phase I study is to
identify the immunogenic HLA-A2.1-restricted peptides from PSA and PAP
that are capable of eliciting CTL that will kill cells expressing these
prostate-related proteins. If funded, the Phase II studies will be
targeted to develop this peptide(s) into a CTL-inducing immunotherapeutic
for treatment of advanced prostate cancer.
StatusFinished
Effective start/end date1/1/956/30/95

ASJC

  • Medicine(all)